In a recent regulatory filing with the SEC, it was disclosed that Fordyce Marshall, serving as President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), executed sales of company Class A Common Stock totaling roughly $679,747 on May 12, 2026. The divestment was carried out through two distinct transaction groups.
The first portion of the sale involved the disposal of 14,219 shares. These were sold at a weighted-average price of $36.6396 per share, with individual transaction prices fluctuating between $35.96 and $36.94. The second portion consisted of 4,281 shares, which were sold at a weighted-average price of $37.0868 per share, with the price range for these specific trades spanning from $36.97 to $37.15.
Executive Holdings and Trading Structure
These sales were not spontaneous market moves but were performed pursuant to a Rule 10b5-1 trading plan, which Marshall had adopted on January 9, 2026. Following the completion of these transactions, Marshall maintains a significant stake in the company. He directly holds 216,744 shares of Class A Common Stock. Furthermore, he maintains indirect holdings through two separate entities: 122,949 shares held via a Grantor Retained Annuity Trust (GRAT) and 99,081 shares held through a Trust.
Market Context and Analyst Sentiment
The insider activity occurs within a complex period for the stock's performance. While VERA has seen an 81% return over the preceding year, the share price has experienced a 23% decline during the current year to date. At the time of reporting, the stock was trading at $39.18. Despite the recent year-to-date drop, some financial analysis suggests the stock may be undervalued.
Recent institutional sentiment toward Vera Therapeutics has been notably positive. Wolfe Research recently upgraded the company's rating from Peerperform to Outperform, establishing a price target of $88.00. This upgrade followed the resolution of uncertainty surrounding a Vertex-related catalyst. Similarly, BofA Securities maintained a Buy rating on the stock with a price target of $66.00. Analyst Dina Ramadane noted that these assessments follow interim Phase 3 trial data from Vertex, which is a primary competitor in the space, regarding their anti-BAFF/APRIL drug for IgAN patients.
Corporate Governance and Financial Position
Beyond insider trading, Vera Therapeutics has undergone leadership expansion. The company recently appointed Christopher Hite to its board of directors as an independent member. Hite brings extensive biopharmaceutical expertise, currently holding the position of Executive Vice President and Vice Chairman at Royalty Pharma, with a professional history that includes roles such as Vice Chairman of Banking, Capital Markets and Advisory at Citi and Global Head of Healthcare Investment Banking at Lehman Brothers.
From a balance sheet perspective, the company's financial standing is characterized by holding more cash than debt.